United Therapeutics (UTHR) News Today $367.38 -2.29 (-0.62%) (As of 10:03 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Worldquant Millennium Advisors LLC Sells 34,562 Shares of United Therapeutics Co. (NASDAQ:UTHR)Worldquant Millennium Advisors LLC lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 81.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,688 shares of the biotechnology company's sDecember 9 at 4:57 AM | marketbeat.com5,769 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Dorsey Wright & AssociatesDorsey Wright & Associates purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,769 shares of the biotechnology company's stock, valuedDecember 8 at 6:49 AM | marketbeat.comMain Management ETF Advisors LLC Purchases Shares of 2,328 United Therapeutics Co. (NASDAQ:UTHR)Main Management ETF Advisors LLC purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,328 shares of the biotechnology company's stock, valued at approximately $834,0December 8 at 6:37 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Position Cut by State Street CorpState Street Corp lowered its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 2.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,238,224 shares of the biotechnologyDecember 8 at 5:10 AM | marketbeat.comBrokerages Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $370.86December 8 at 1:39 AM | americanbankingnews.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) EVP Sells 7,700 Shares of StockDecember 7 at 7:15 AM | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $2,882,649.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.December 6 at 4:49 PM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Chevy Chase Trust Holdings LLCChevy Chase Trust Holdings LLC increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 106.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,049 shares of the biotechnology coDecember 6 at 4:42 AM | marketbeat.comUnited Therapeutics management to meet with OppenheimerDecember 6 at 2:56 AM | markets.businessinsider.comJanus Henderson Group PLC Acquires 50,409 Shares of United Therapeutics Co. (NASDAQ:UTHR)Janus Henderson Group PLC grew its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 12.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 460,419 shares of the biotechnology company's stock after buying an additionaDecember 5, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT CorpBRITISH COLUMBIA INVESTMENT MANAGEMENT Corp trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 17.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,034 shares of the biotechnologyDecember 5, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by BrokeragesShares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assDecember 5, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 42.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 64,031 shares of the biotechnology company's stock after sellingDecember 4, 2024 | marketbeat.comEdgestream Partners L.P. Buys New Position in United Therapeutics Co. (NASDAQ:UTHR)Edgestream Partners L.P. purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 4,421 shares of the biotechnology company's stock, valued at approximately $December 4, 2024 | marketbeat.comPDT Partners LLC Sells 5,560 Shares of United Therapeutics Co. (NASDAQ:UTHR)PDT Partners LLC decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 85.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 980 shares of the biotechnology company's stock after seDecember 4, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $76.21 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 12.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21December 3, 2024 | marketbeat.comErste Asset Management GmbH Acquires New Stake in United Therapeutics Co. (NASDAQ:UTHR)Erste Asset Management GmbH acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 45,266 shares of the biotechnology company's stock,December 2, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Stake Trimmed by Zurcher Kantonalbank Zurich CantonalbankZurcher Kantonalbank Zurich Cantonalbank cut its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 14.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,123 shares of the bioteDecember 2, 2024 | marketbeat.comBNP Paribas Financial Markets Has $12.25 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)BNP Paribas Financial Markets lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 38.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,192 shares of the biotechnology company's sDecember 2, 2024 | marketbeat.comTrue Wealth Design LLC Reduces Position in United Therapeutics Co. (NASDAQ:UTHR)True Wealth Design LLC trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 95.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 169 shares of the biotechnology company's stock after selling 3,274 shares durDecember 1, 2024 | marketbeat.comFmr LLC Has $386.17 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)Fmr LLC lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 41.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,077,628 shares of the biotechnology company's stockDecember 1, 2024 | marketbeat.comBank of Montreal Can Decreases Stake in United Therapeutics Co. (NASDAQ:UTHR)Bank of Montreal Can decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 38,013 shares of the biotechnology company's stock after sDecember 1, 2024 | marketbeat.comCerity Partners LLC Buys 4,005 Shares of United Therapeutics Co. (NASDAQ:UTHR)Cerity Partners LLC grew its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 82.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,886 shares of the biotechnology comDecember 1, 2024 | marketbeat.comMartingale Asset Management L P Sells 5,664 Shares of United Therapeutics Co. (NASDAQ:UTHR)Martingale Asset Management L P trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 13.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,102 shares of the biotechnology company'November 30, 2024 | marketbeat.comCrawford Fund Management LLC Has $8.49 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)Crawford Fund Management LLC decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 29.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,692 shares of the biotechnoNovember 29, 2024 | marketbeat.comThe 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314%November 29, 2024 | finance.yahoo.comGlenmede Trust Co. NA Purchases 4,145 Shares of United Therapeutics Co. (NASDAQ:UTHR)Glenmede Trust Co. NA raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 68,605 shares of the biotechnology company's stNovember 28, 2024 | marketbeat.comBridgewater Associates LP Raises Position in United Therapeutics Co. (NASDAQ:UTHR)Bridgewater Associates LP lifted its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 384.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,755 shares of the biotechnology company's stockNovember 28, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 SharesUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $960,576.75. This represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.November 27, 2024 | marketbeat.comDai ichi Life Insurance Company Ltd Sells 1,412 Shares of United Therapeutics Co. (NASDAQ:UTHR)Dai ichi Life Insurance Company Ltd trimmed its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 15.3% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 7,790 shares of the biotechnology company's stock after selling 1,412 shares duringNovember 27, 2024 | marketbeat.comLoomis Sayles & Co. L P Has $53.21 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)Loomis Sayles & Co. L P reduced its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 36.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 148,481 shares of the biotechnology company's stock aNovember 26, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Trims Stock Position in United Therapeutics Co. (NASDAQ:UTHR)Charles Schwab Investment Management Inc. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 369,955 shares of the biotechnology company'sNovember 25, 2024 | marketbeat.comSwedbank AB Sells 7,718 Shares of United Therapeutics Co. (NASDAQ:UTHR)Swedbank AB lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 414,937 shares of the biotechnology cNovember 24, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Position Trimmed by Citigroup Inc.Citigroup Inc. trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 90.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 147,979 shares of the biotechnology company's stock after selling 1,477,626 shares duringNovember 24, 2024 | marketbeat.comIntech Investment Management LLC Sells 6,815 Shares of United Therapeutics Co. (NASDAQ:UTHR)Intech Investment Management LLC reduced its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 45.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,288 shares of the biotechnologyNovember 24, 2024 | marketbeat.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Stake in United Therapeutics Co. (NASDAQ:UTHR)BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 64.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 32,092 shares of the biotechnology company's stock after buying an additional 1November 24, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Reduces Stock Position in United Therapeutics Co. (NASDAQ:UTHR)Connor Clark & Lunn Investment Management Ltd. decreased its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 79.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,959 shaNovember 24, 2024 | marketbeat.comThrivent Financial for Lutherans Has $5.14 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)Thrivent Financial for Lutherans raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 33.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,332 shares of the biotechnoNovember 24, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 7,700 SharesNovember 23, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $2,828,672.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.November 22, 2024 | marketbeat.comZacks Research Issues Positive Forecast for UTHR EarningsUnited Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities researchers at Zacks Research lifted their Q4 2024 earnings per share (EPS) estimates for United Therapeutics in a note issued to investors on Tuesday, November 19th. Zacks Research analyst R. Department now forecasts that the biotechNovember 22, 2024 | marketbeat.comWhat is Zacks Research's Forecast for UTHR FY2024 Earnings?United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Research analysts at Zacks Research upped their FY2024 EPS estimates for shares of United Therapeutics in a note issued to investors on Tuesday, November 19th. Zacks Research analyst R. Department now forecasts that the biotechnology company wNovember 21, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Swiss National BankSwiss National Bank decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 5.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 125,055 shares of the biotechnology company's stock afterNovember 21, 2024 | marketbeat.com14,800 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Premier Fund Managers LtdPremier Fund Managers Ltd acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 14,800 shares of the biotechnology comNovember 20, 2024 | marketbeat.comSeizert Capital Partners LLC Has $13.94 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)Seizert Capital Partners LLC lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 59.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,906 shares of the biotechnology companNovember 17, 2024 | marketbeat.comEmpowered Funds LLC Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR)Empowered Funds LLC reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 51.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,229 shares of the biotechnology companyNovember 16, 2024 | marketbeat.comCornercap Investment Counsel Inc. Has $726,000 Position in United Therapeutics Co. (NASDAQ:UTHR)Cornercap Investment Counsel Inc. cut its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 61.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,027 shares of the biotechnology company's stock after selling 3,257 shares during the quarterNovember 16, 2024 | marketbeat.comUnited Therapeutics: Competitive Advantages At Such Cheap Multiples Scream BuyNovember 15, 2024 | seekingalpha.comUnited Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles LoomNovember 15, 2024 | seekingalpha.comKBC Group NV Decreases Position in United Therapeutics Co. (NASDAQ:UTHR)KBC Group NV decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 26.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,886 shares of the biotechnology company's stock aNovember 15, 2024 | marketbeat.com Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race… Click here to see a unique election-year trade UTHR Media Mentions By Week UTHR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UTHR News Sentiment▼1.550.69▲Average Medical News Sentiment UTHR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UTHR Articles This Week▼1710▲UTHR Articles Average Week Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALNY News BIIB News INCY News NBIX News BMRN News EXAS News EXEL News RGEN News MDGL News HALO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UTHR) was last updated on 12/9/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UTHR Stock Alerts